Harrow to acquire global rights to TYRVAYA nasal spray from ViatrisAug 6Regulatory decisioncyclosporine ophthalmic solutionHarrow Inc
Viatris raises 2026 guidance, reports FDA approvals and Tyrvaya sale in Q2 updateAug 6Quarterly updatevareniclineViatris Inc.
Mylan doxepin label update approved; Viatris-linked contact lens comfort trial begins recruitingJul 16Weekly roundup, 2 itemsdoxepinViatris Inc.
Sign inSign in